Please use this identifier to cite or link to this item: http://dx.doi.org/10.14279/depositonce-11905
For citation please use:
Main Title: Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19
Author(s): Bezbaruah, Rajashri
Borah, Pobitra
Kakoti, Bibhuti Bhushan
Al-Shar’I, Nizar A.
Chandrasekaran, Balakumar
Jaradat, Da’san M. M.
Al-Zeer, Munir A.
Abu-Romman, Saeid
Type: Article
Language Code: en
Abstract: Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, arose at the end of 2019 as a zoonotic virus, which is the causative agent of the novel coronavirus outbreak COVID-19. Without any clear indications of abatement, the disease has become a major healthcare threat across the globe, owing to prolonged incubation period, high prevalence, and absence of existing drugs or vaccines. Development of COVID-19 vaccine is being considered as the most efficient strategy to curtail the ongoing pandemic. Following publication of genetic sequence of SARS-CoV-2, globally extensive research and development work has been in progress to develop a vaccine against the disease. The use of genetic engineering, recombinant technologies, and other computational tools has led to the expansion of several promising vaccine candidates. The range of technology platforms being evaluated, including virus-like particles, peptides, nucleic acid (DNA and RNA), recombinant proteins, inactivated virus, live attenuated viruses, and viral vectors (replicating and non-replicating) approaches, are striking features of the vaccine development strategies. Viral vectors, the next-generation vaccine platforms, provide a convenient method for delivering vaccine antigens into the host cell to induce antigenic proteins which can be tailored to arouse an assortment of immune responses, as evident from the success of smallpox vaccine and Ervebo vaccine against Ebola virus. As per the World Health Organization, till January 22, 2021, 14 viral vector vaccine candidates are under clinical development including 10 nonreplicating and four replicating types. Moreover, another 39 candidates based on viral vector platform are under preclinical evaluation. This review will outline the current developmental landscape and discuss issues that remain critical to the success or failure of viral vector vaccine candidates against COVID-19.
URI: https://depositonce.tu-berlin.de/handle/11303/13112
http://dx.doi.org/10.14279/depositonce-11905
Issue Date: 15-Apr-2021
Date Available: 18-May-2021
DDC Class: 570 Biowissenschaften; Biologie
Subject(s): COVID-19
vaccines
viral vector
ChAdOx1-S
Ad5-nCoV
MERS-CoV
License: https://creativecommons.org/licenses/by/4.0/
Journal Title: Frontiers in Molecular Biosciences
Publisher: Frontiers
Publisher Place: Lausanne
Volume: 8
Article Number: 635337
Publisher DOI: 10.3389/fmolb.2021.635337
EISSN: 2296-889X
Appears in Collections:FG Angewandte Biochemie » Publications

Files in This Item:
fmolb-08-635337.pdf
Format: Adobe PDF | Size: 1.11 MB
DownloadShow Preview
Thumbnail
fmolb-08-635337-g001.tif
Format: TIFF | Size: 1.36 MB
Download
Thumbnail

Item Export Bar

This item is licensed under a Creative Commons License Creative Commons